Jennison Associates LLC Boosts Position in Kestra Medical Technologies, Ltd. $KMTS

Jennison Associates LLC lifted its stake in shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) by 79.0% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 134,272 shares of the company’s stock after acquiring an additional 59,272 shares during the period. Jennison Associates LLC owned 0.26% of Kestra Medical Technologies worth $2,226,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Eventide Asset Management LLC purchased a new position in shares of Kestra Medical Technologies during the 1st quarter worth $6,853,000. Omega Fund Management LLC acquired a new stake in shares of Kestra Medical Technologies during the 1st quarter worth about $44,754,000. Alyeska Investment Group L.P. acquired a new stake in shares of Kestra Medical Technologies during the 1st quarter worth about $2,492,000. Caas Capital Management LP acquired a new stake in shares of Kestra Medical Technologies during the 1st quarter worth about $1,470,000. Finally, Invesco Ltd. acquired a new stake in shares of Kestra Medical Technologies during the 1st quarter worth about $4,984,000.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d)” rating on shares of Kestra Medical Technologies in a research report on Wednesday, October 8th. Wells Fargo & Company cut their price objective on Kestra Medical Technologies from $28.00 to $27.00 and set an “overweight” rating for the company in a research report on Thursday, July 17th. Finally, Wall Street Zen downgraded Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Sunday, September 28th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Kestra Medical Technologies presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.33.

Kestra Medical Technologies Stock Performance

NASDAQ KMTS opened at $27.38 on Friday. The company has a market cap of $1.41 billion and a P/E ratio of -10.74. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.84 and a quick ratio of 6.84. The stock has a 50-day moving average of $22.68 and a two-hundred day moving average of $20.33. Kestra Medical Technologies, Ltd. has a 1-year low of $13.25 and a 1-year high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings data on Thursday, September 11th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.20. The company had revenue of $19.37 million for the quarter, compared to analyst estimates of $17.68 million. Kestra Medical Technologies has set its FY 2026 guidance at EPS.

Kestra Medical Technologies Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.